We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





BPM Presents Urine-Based Kidney Disease Risk Test at MEDICA 2026

By LabMedica International staff writers
Posted on 17 Nov 2026

Bio Preventive Medicine Corp. More...

(BPM, Hsinchu County, Taiwan) showcases its DNlite urinary biomarker test at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. The company specializes in post-translationally modified protein biomarkers and in vitro diagnostics (IVD), focusing on identifying patients at risk of kidney disease progression before substantial deterioration in renal function occurs.

The featured DNlite (uPTM-FetA ELISA) test is designed to assess kidney function prognosis by measuring urinary post-translationally modified Fetuin-A (uPTM-FetA). The biomarker is associated with cellular stress involving kidney podocytes and tubular cells. The assay aims to distinguish patients at increased risk of rapid kidney function decline from those with more stable renal function.

Conventional kidney assessments rely on markers such as the urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). However, these measurements may not fully capture early kidney injury or distinguish patients likely to experience rapid progression. DNlite is designed to complement existing tests by providing additional prognostic information to support earlier risk assessment.

The assay requires a routine random urine sample, avoiding the need for fasting blood collection or invasive procedures. Its ELISA format is intended for use in qualified clinical laboratories. DNlite provides prognostic information that can be considered alongside conventional clinical assessments, potentially supporting more individualized monitoring and treatment planning.

DNlite has obtained European Union In Vitro Diagnostic Regulation (IVDR) Class C certification for prognostic assessment in patients with type 2 diabetes and kidney transplant recipients. BPM reports commercial authorizations across more than 42 countries in Europe, the Middle East, Asia, and Latin America, supporting the test's availability in multiple international markets.

Clinical evidence supporting DNlite includes research involving participants from the CREDENCE trial. An analysis of 2,429 patients with type 2 diabetes and chronic kidney disease found that urinary uPTM-FetA independently predicted adverse renal outcomes beyond conventional markers, including UACR and eGFR. The findings suggest that the biomarker may provide additional information for identifying patients at increased risk of progression.

The company is also exploring the adaptation of its uPTM-FetA biomarker technology to automated clinical chemistry and chemiluminescence immunoassay platforms. These development initiatives aim to extend the test beyond its existing ELISA format and support integration into routine laboratory workflows through partnerships with diagnostic instrument manufacturers.

Additional collaboration opportunities include regional distribution, reference laboratory testing, pharmaceutical clinical trials, and integrated kidney care programs. BPM is investigating the potential use of its biomarkers to identify patients at increased risk of disease progression for clinical studies and support research into treatment monitoring and precision kidney care.

BPM exhibits at Booth C26-1 in Hall 3 within the Taiwan Flagship Pavilion. The company uses its participation at MEDICA 2026 to engage with diagnostic manufacturers, laboratory operators, healthcare providers, and research partners interested in urinary biomarker testing and kidney disease risk assessment technologies.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.